Get our newsletter delivered directly to your inbox
I have already subscribed | Do not show this message again
Your email has been successfully registered.
Pfizer's anti-COVID-19 drug, Paxlovid, will be available for sale in private hospitals and pharmacies by prescription after being authorized by the country's National Health Surveillance Agency (ANVISA).
The decision was taken unanimously by ANVISA's board of directors. Paxlovid, manufactured by the U.S. laboratory Pfizer, was authorized in Brazil for emergency use at the end of March.
Anvisa approves sale of drug against Covid19. The drug Paxlovid, by Pfizer, may be sold in pharmacies with a prescription. Unlike chloroquine, the efficacy of this drug has been proven.
The Food and Drug Administration (FDA) in the U.S. has approved Paxlovid, as has the European Medicines Agency (EMA) in Europe, Canada, China, Australia, Japan, UK and Mexico.
The World Health Organization (WHO) has strongly recommended its use for patients with mild and moderate cases of COVID-19 who are at increased risk of hospitalization.
Noting that the agency's decision to put the drug on the private market will increase access to COVID-19 treatment, ANVISA director Meiruze Freitas said that vaccination remains the best approach to prevent COVID-19, hospitalizations and deaths.